VINTOR 2000IU INJECTION

Dosage

Children: Refer to specific product guidelines as dosages may vary based on the active ingredient and clinical condition.

Adults: Refer to specific product guidelines as dosages may vary based on the active ingredient and clinical condition.

Mechanism of action

The specific mechanism of action for a concentrated drug depends on the active ingredients present in the formulation. Generally, concentrated drugs exert their effects by interacting with specific receptors or enzymes in the body, altering physiological processes. For example, concentrated analgesics may inhibit cyclooxygenase enzymes, leading to reduced production of prostaglandins, resulting in pain relief. Similarly, concentrated antibiotics may inhibit bacterial cell wall synthesis, leading to bacterial death.

Pharmacodynamics

Pharmacodynamics of concentrated drugs involves understanding the relationship between drug concentration at the site of action and the resulting therapeutic effect. Concentration-dependent effects may be observed, where higher concentrations lead to increased efficacy but also a risk of toxicity. The therapeutic window, which is the range between effective and toxic concentrations, is critical in guiding the safe use of concentrated formulations.

Pharmacokinetics

Pharmacokinetics of concentrated drugs encompasses absorption, distribution, metabolism, and excretion (ADME). Concentrated formulations may have altered pharmacokinetic profiles compared to standard formulations due to their higher potency. Absorption may be faster or more extensive, depending on the formulation. Distribution may be influenced by factors such as lipophilicity and plasma protein binding. Metabolism may occur in the liver, primarily through enzymatic pathways, while excretion typically occurs via renal or biliary routes.

Pregnancy

Consult a healthcare professional before use. Safety in pregnancy has not been established.

Breast-feeding

Consult a healthcare professional before use. Safety during breastfeeding has not been established.

Storage

Store in a cool, dry place away from direct sunlight. Keep out of reach of children.

Indications

• Anemia associated with chronic kidney disease
• Anemia in patients with cancer undergoing chemotherapy
• Anemia in patients with HIV receiving zidovudine therapy
• Anemia of prematurity in neonates

Dosage

Children: Refer to the BNF for Children for specific dosing recommendations based on the child's age, weight, and clinical condition.

Adults: Refer to specific clinical guidelines or the BNF for exact dosing recommendations based on the condition being treated.

Mechanism of action

Erythropoietin binds to the erythropoietin receptor (EPOR) on erythroid progenitor cells in the bone marrow. This interaction activates the JAK2/STAT5 signaling pathway, leading to the proliferation and differentiation of these progenitor cells into erythrocytes. Additionally, erythropoietin enhances the survival of erythroid progenitors by inhibiting apoptosis.

Pharmacodynamics

The pharmacodynamic effects of erythropoietin include increased red blood cell count, hemoglobin levels, and overall improvement in oxygen-carrying capacity of the blood. The onset of action typically occurs within days to weeks, as erythropoiesis is a time-dependent process. The duration of action can vary, depending on the formulation used and the patient's response.

Pharmacokinetics

Erythropoietin has a relatively short half-life of approximately 4 to 13 hours in circulation. It is primarily eliminated by the kidneys, and its pharmacokinetics can be influenced by factors such as renal function, dosage, and route of administration. The bioavailability of erythropoietin is affected by the route of administration, with subcutaneous administration providing lower bioavailability compared to intravenous administration.

Contra-indications

• Uncontrolled hypertension
• Known hypersensitivity to erythropoietin or any of its components
• Pure red cell aplasia (PRCA) due to erythropoiesis-stimulating agents

Adverse effects

• Hypertension
• Headache
• Fatigue
• Nausea
• Vomiting
• Diarrhea
• Injection site reactions
• Thromboembolic events
• Seizures

Interactions

• Iron supplements may enhance the effect of erythropoietin
• Anticoagulants may have an increased risk of thrombosis when used with erythropoietin
• Other agents that may increase blood pressure should be used with caution

Precautions

• Monitor blood pressure regularly during treatment
• Evaluate iron status prior to and during treatment
• Use caution in patients with a history of thromboembolic events
• Consider the risk of PRCA in patients with a history of antibodies to erythropoietin

Pregnancy

Erythropoietin should only be used during pregnancy if the potential benefit justifies the potential risk to the fetus. Limited data on the use of erythropoietin in pregnant women is available.

Breast-feeding

It is not known whether erythropoietin is excreted in human milk. Caution should be exercised when administering to breastfeeding women.

Storage

Store in a refrigerator at 2-8 degrees Celsius. Do not freeze. Protect from light.

Formulations

• Erythropoietin injection solution
• Erythropoietin biosimilars